Abstract:
The extracellular matrix (ECM) plays an important role in the progression of cancer. Collagen is the most abundant component in ECM, and is involved in the biological formation of cancer. Although type XI collagen is a minor fibrillar collagen, collagen XI alpha 1 chain (COL11A1) expression has been found to be upregulated in a variety of human cancers including colorectal, esophagus, glioma, gastric, head and neck, lung, ovarian, pancreatic, salivary gland, and renal cancers. High levels of COL11A1 usually predict poor prognosis, owing to its association with angiogenesis, invasion, and drug resistance in cancer. However, little is known about the specific mechanism through which COL11A1 regulates tumor progression. Here I will present a summary of what we have done about COL11A1 in EOC, as well as the newly discoveries.
Audience Take Away Notes:
- COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.
- COL11A1 promotes tumor aggressiveness via the TGF-β1-MMP3 axis.
- COL11A1 confers chemoresistance on ovarian cancer cells through activation of Akt/c/EBPβ pathway and PDK1 stabilization.
- COL11A1 or Akt could be used as prognosis predictive markers or as the target for drug design in EOC.
